Piramal Pharma Limited’s shares fell 5% after the company received a Form-483 from the US FDA following an inspection of its Turbhe facility. The General GMP (Good Manufacturing Practices) audit, conducted from February 11 to 17, 2025, resulted in six observations.
The observations primarily focus on procedural improvements and operational practices, with no data integrity concerns raised. Piramal Pharma has assured stakeholders that it is preparing a detailed response to address the FDA’s feedback within the stipulated timelines.
Piramal Pharma’s stock opened at ₹190.00, reaching a high of ₹192.34 and a low of ₹187.01. The stock remains significantly below its 52-week high of ₹307.90 but well above the 52-week low of ₹114.35.
Piramal Pharma Q3 results
Piramal Pharma reported a decline in net profit for Q3 FY25, falling to ₹3.7 crore from ₹10.1 crore in the same quarter last year. However, the company achieved a 12.5% increase in income from operations, reaching ₹2,204.2 crore compared to ₹1,958.6 crore in Q3 FY24.
Despite the drop in net profit, EBITDA surged by 25.8% to ₹337.7 crore, with the EBITDA margin improving to 15.3% from 13.7% a year ago. The company maintained a stable net-debt-to-EBITDA ratio at 2.8x. Growth in the Contract Development and Manufacturing Organization (CDMO) segment was driven by strong demand for on-patent commercial manufacturing and robust performance in the generic API sector. The Complex Hospital Generics (CHG) business also performed well, particularly in the US, where inhalation anesthesia products like Sevoflurane and Isoflurane contributed to growth.
Piramal Pharma’s India Consumer Healthcare (ICH) division continued to expand, with Power Brands such as Little’s, Polycrol, and CIR registering 19% year-on-year growth, outperforming the industry despite subdued consumer demand.
